Modality
Bispecific Ab
MOA
Cl18.2
Target
EZH2
Pathway
Ferroptosis
MSObesity
Development Pipeline
Preclinical
~Apr 2017
→ ~Jul 2018
Phase 1
~Oct 2018
→ ~Jan 2020
Phase 2
Apr 2020
→ Mar 2029
Phase 2Current
NCT08907623
307 pts·MS
2020-04→2029-03·Not yet recruiting
307 total pts1 indication
Phase 3
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (1)
2029-03-183.0y awayPh3 Readout· MS
Trial Timeline
Q2Q3Q42021Q2Q3Q42022Q2Q3Q42023Q2Q3Q42024Q2Q3Q42025Q2Q3Q42026Q2Q3Q42027Q2Q3Q42028Q2Q3Q42029Q2
P2/3
Not yet…
Catalysts
Ph3 Readout
2029-03-18 · 3.0y away
MS
Not yet recruiting|StartCompletionToday
Trials (1)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT08907623 | Phase 2/3 | MS | Not yet recr... | 307 | LiverFat |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| Zorivorutinib | Bristol-Myers Squibb | Approved | DLL3 | |
| DSN-2247 | Daiichi Sankyo | NDA/BLA | EZH2 | |
| Elrarapivir | Regeneron | Phase 1 | GIP-R | |
| VKT-6548 | Viking Therapeutics | Phase 2/3 | PD-L1 | |
| Tiratapinarof | Intellia | NDA/BLA | APOC3 | |
| ELV-1411 | Enliven | NDA/BLA | HER2 | |
| Gelitapinarof | MacroGenics | Approved | CDK2 | |
| Voxabrutinib | Annexon | Phase 1/2 | EZH2 | |
| SLD-1824 | Solid Bio | Phase 2 | EZH2 | |
| Lisoinavolisib | Schrodinger | Approved | TIGIT |